Last reviewed · How we verify

NCT05043480

Pilot Study On Pulsed Electromagnetic Field Therapy For Osteosarcopenia

Status unknown NA Last updated 14 September 2021
What this trial tests

NA trial testing PEMF in Sarcopenia in 80 participants. Status unknown.

Timeline
1 October 2021
Primary endpoint
31 December 2022
31 December 2022

Quick facts

Lead sponsorLouis Tee
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment80
Start date1 October 2021
Primary completion31 December 2022
Estimated completion31 December 2022
Sites1 location across Singapore

Drugs / interventions tested

Conditions studied

Sponsor

Louis Tee

Who can join

Adults 65 to 100, any sex, with Sarcopenia or Osteopenia or Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, single-site, single arm pilot study aims to assess the efficacy of Pulsed Electromagnetic Field (PEMF) exposure in the reduction of the decline in muscle strength, function and bone mineral density (BMD) in osteosarcopenia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PEMF

Trials testing the same drug.

Other recruiting trials for Sarcopenia

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05043480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing